Name | SR 49059,(2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide |
---|---|
Synonyms |
reclovaptan
cis-Ned 19 INDOL-2-YLCARBONYL)-L-PROLINAMIDE Relcovaptan SR 49059 |
Description | SR 49059 (SR-49059) is a potent, orally active, selective vasopressin V1a antagonist with a Ki vaule of 1.4 nM[1]. |
---|---|
Related Catalog | |
Target |
Ki: 1.4±0.3 nM (vasopressin V1a)[1]. |
In Vivo | SR 49059 (SR-49059) (2 mg/kg and 30 mg/kg; i.p.; once) shows neuroprotective effects in ischemic brain injury when injected early after occlusion of the middle cerebral artery (MCA)[2]. Animal Model: Male Wistar rats, weighing 300 to 350 g, cerebral focal ischemia model[2] Dosage: 2 mg/kg and 30 mg/kg dissolved in 10% dimethyl sulfoxide Administration: Intraperitoneal injection, once Result: Significantly reduced infarction volume measured at 48 hours after the arterial occlusion. Reduced neurological deficits and ischemic brain edema. |
References |
Density | 1.499g/cm3 |
---|---|
Boiling Point | 868ºC at 760mmHg |
Molecular Formula | C28H27Cl2N3O7S |
Molecular Weight | 620.50 |
Flash Point | 478.8ºC |
Exact Mass | 619.09500 |
PSA | 147.85000 |
LogP | 5.08430 |
Vapour Pressure | 0mmHg at 25°C |
Index of Refraction | 1.664 |
Storage condition | 2-8°C |
RIDADR | NONH for all modes of transport |
---|